Evidence map›Paper›PMID 42233010›Full record

ArticleFrontiers in immunology2026

Establishment and optimization of an

Joyce Lübbers, Kaila Orlandini, Emily Podob, Jeffrey Fernandez, Jolaine M Wilson, Marjolein van Heerden, Jeroen Zeijpveld, Joan van Kregten, Peter T Buckley, Germie van den Dobbelsteen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joyce Lübbers *Bacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.
Kaila Orlandini *Infectious Diseases and Vaccines, Johnson and Johnson, Spring House, PA, United States.
Emily PodobInfectious Diseases and Vaccines, Johnson and Johnson, Spring House, PA, United States.
Jeffrey FernandezInfectious Diseases and Vaccines, Johnson and Johnson, Spring House, PA, United States.
Jolaine M WilsonScientific & In Vivo Strategies, Johnson and Johnson, Spring House, PA, United States.
Marjolein van HeerdenPreclinical Sciences and Translational Safety, Johnson and Johnson, Beerse, Belgium.
Jeroen ZeijpveldBacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.
Joan van KregtenBacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.
Peter T BuckleyInfectious Diseases and Vaccines, Johnson and Johnson, Spring House, PA, United States.
Germie van den DobbelsteenBacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.
Kirsten L BairInfectious Diseases and Vaccines, Johnson and Johnson, Spring House, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Urinary tract infections caused by uropathogenic Methods: Foley balloon catheters were used to challenge minipigs intraurethrally with UPEC strain UTI89. Urine collected after challenge was plated for bacterial enumeration and recovered bacteria was tested for agglutination and whole genome sequencing. Results: Through intraurethral challenge with UTI89, we were able to establish infection for 14 days. Agglutination and whole genome sequencing revealed that 75% of the animals were infected with UTI89 challenge strain, while in 25% of the animals, a different Discussion: Altogether, we describe a novel minipig UTI model using an intraurethral challenge with UPEC strain UTI89 that can be used to assess vaccines and treatment efficacy; and will serve to bridge the gap between preclinical findings and clinical outcomes in humans.

Indexed as

Disease Models, AnimalEscherichia coli InfectionsUrinary Tract InfectionsUropathogenic Escherichia coliAnimalsFemaleSwineSwine, Miniatureagglutinationbacterial loadminipigserotypingUPECurinary tract infectionUTI89whole genome sequencing

Identifiers

PMID42233010
PMCPMC13223159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.